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Highly Complex Peptide Aggregates of the S100
Fused-Type Protein Hornerin Are Present in
Human Skin
Zhihong Wu1,4, Ulf Meyer-Hoffert1,4, Katrin Reithmayer2, Ralf Paus2,3, Britta Hansmann1, Yinghong He1,
Joachim Bartels1, Regine Gla¨ser1, Ju¨rgen Harder1 and Jens-Michael Schro¨der1
Human hornerin (HRNR) is a 245 kDa S100 fused-type protein which contains 95% tandem quasi-repeating
glycine- and serine-rich domains. Previously HRNR was not thought to be expressed in healthy skin; however,
we purified an HRNR peptide fragment from stratum corneum. Moreover, we found that HRNR mRNA is
expressed in skin biopsies from different sites as head, trunk, legs, hands, and feet. In cultured human
epidermal keratinocytes, HRNR mRNA expression was transiently induced during Ca2þ -dependent differentia-
tion. Immunostaining using distinct antibodies generated against four putative HRNR domains revealed strong
HRNR immunoreactivity in healthy epidermis as well as in the entire outer root sheath of normal human scalp
hair follicles. In lesions from psoriasis and atopic dermatitis patients, HRNR immunoreactivity was reduced
compared with uninvolved skin of these patients. Electrospray ionization mass spectrometry and Western blot
analyses revealed that HRNR is a highly degradable protein that forms complex high molecular weight peptide
aggregates. Our findings suggest that HRNR is expressed in healthy skin and give insight into the complex
biology of this protein. HRNR and its degradation products might contribute to the barrier function of healthy
human skin.
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INTRODUCTION
The physical barrier of the skin is formed by keratinocytes
that have undergone metabolic and structural modifications
during their terminal differentiation. Keratinocytes migrate
from the basal layer toward the upper layers before ultimately
ending with the demise of the keratinocytes via cornification,
a specialized form of programmed cell death (Lippens et al.,
2000) and transformation into corneocytes (Elias, 2007).
During the final stages of terminal differentiation, an
insoluble protein structure, the cornified cell envelope, is
assembled to replace the plasma membrane in corneocytes,
thereby determining essential properties of normal barrier
function (Kalinin et al., 2001; Candi et al., 2005) such as
resistance to mechanical stress (Elias, 2005; Elias and Choi,
2005).
Most cornified cell envelope precursor proteins are
encoded by tightly clustered genes within the epidermal
differentiation complex (EDC), a 1.6-Mb region of genomic
DNA on human chromosome 1q21 (Volz et al., 1993;
Marenholz et al., 1996; Mischke et al., 1996). These include
two major precursor proteins of the cornified cell envelope,
involucrin (Steinert and Marekov, 1995, 1997) and loricrin
(Mehrel et al., 1990), and four protein families, such as S100
proteins (S100A1-S100A9) (Schafer et al., 1995), small
proline-rich region proteins (Cabral et al., 2001), late
cornified envelope (LCE) proteins (Jackson et al., 2005) and
S100 fused-type proteins (SFTPs). In human, SFTPs include
profilaggrin (Presland et al., 1992), trichohyalin (Lee et al.,
1993), repetin (Huber et al., 2005), cornulin (Xu et al., 2000;
Contzler et al., 2005), and hornerin (HRNR) (Takaishi et al.,
2005). They are generally thought to be cross-linked by
transglutaminases to maintain an intact physical barrier
with characteristic resistance and insolubility. Very little is
known about biological functions of most SFTPs, although
filaggrin (FLG) has recently been identified as an integral part
of the epidermis with a key role in maintaining the barrier
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function (Irvine, 2007; Sandilands et al., 2007; McGrath and
Uitto, 2008), although its importance for stratum corneum
(SC) hydration has been identified two decades earlier (Scott
and Harding, 1986).
It was recently reported that human HRNR is only
expressed in regenerating and psoriatic but not in healthy
skin (Takaishi et al., 2005). In contrast to this report, we
isolated a natural HRNR peptide from SC extracts and
identified the full-length cDNA sequence of the HRNR gene
in foreskin-derived keratinocytes (GenBank accession no.
AY396741, unpublished data). The isolation of an HRNR
peptide prompted us to reanalyze the HRNR protein
expression in healthy and diseased skin. In this study,
we provide strong evidence that HRNR is expressed in
healthy skin.
RESULTS
An HRNR peptide is present in SC extracts
To characterize heparin-bound peptides and proteins in
normal human SC extracts, we previously isolated several
proteins (Harder and Schro¨der, 2005). One of them was
purified from polar high-performance liquid chromatography
(HPLC) fractions and subjected to Tricine–SDS-PAGE
analysis. Only faint bands, if any, were visualized by
Coomassie-, Ponceau- and silver-staining (data not shown).
Electrospray ionization mass spectrometry (ESI–MS) analysis
revealed the presence of a 9.2-kDa peptide. The peptide
yielded the N-terminal 14-amino-acid (AA) sequence
SQHGSGSGHSSGYGQXG by Edman degradation and was
identified as part of repeat domains of the SFTP HRNR (Figure
S1). Five predicted repeat domains, A1 (HRNR245–338), A5
(HRNR1181–1274), A7 (HRNR1651–1744), A9 (HRNR2121–2214),
and A11 (HRNR2591–2684) contain exactly this N-terminal
sequence, but only A11 (Figure 1, predicted mass: 9210.2Da)
fits well with the observed mass of 9209.7 and 9230.6Da
(Na-adduct) (Figure S1). The intensive signal of an ion
corresponding to molecular mass of 9260.5 does not fit with
any other repeat domains such as HRNR245338 (9520.6Da),
HRNR1181–1274 (9219.3Da), HRNR1651–1744 (9328.4Da), and
HRNR2121–2214 (9212.2Da), which all have exactly the same
N-terminal sequence.
The HRNR gene is transcribed in normal human skin
To verify HRNR expression in the skin, we investigated
HRNR mRNA expression in human skin biopsies originating
from different locations by employing qualitative reverse
transcriptase (RT)-PCR and quantitative real-time PCR with
one pair of optimized intron-spanning primers. We detected
HRNR transcripts with RT–PCR in all tissue biopsies
examined, such as those from head, face, neck, shoulders,
trunk, legs, and feet (Figure 2a). Although detectable, the
expression levels of HRNR mRNA in all these samples were
very low (0.1–3 copies per 10 ng of total RNA or per
B1,000 cells (Figure 2a). Indeed, HRNR mRNA expression
levels in human skin were at least four orders of magnitude
lower than that of FLG (Figure 2b). At different anatomical
sites, both HRNR and FLG exhibited different expression
levels (Figure 2b).
HRNR mRNA is transiently expressed in cultured primary
keratinocytes
To show that HRNR is expressed in keratinocytes, we
performed RT–PCR of cultured keratinocytes. Because many
of the SFTP members are known to be expressed at a late
stage during keratinocyte differentiation, keratinocyte differ-
entiation was induced in vitro by increased Ca2þ concentra-
tion in culture media (Yuspa et al., 1989). Our real-time PCR
analysis revealed that HRNR mRNA expression was in-
creased 4 days in the presence of 1.7mM Ca2þ , but yet
declined rapidly after 6 days stimulation (Figure 3a). In
contrast, FLG mRNA expression was increased steadily
during keratinocyte differentiation and remained at high
levels up to day 8 (Figure 3b).
Prominent HRNR immunoreactivity is found in healthy human
skin epithelium
To further confirm HRNR expression in the skin, immuno-
histochemical analysis of healthy skin specimens were
performed. A panel of antibodies (Abs) were generated against
four recombinant HRNR domain peptides (Figure 4). In
paraffin-embedded human skin sections, HRNR expression
was detected in all healthy skin specimens investigated
(n450). Notably, different Abs resulted in diverse staining
patterns. For example, in paraffin-embedded skin sections, the
anti-HRNR1 polyclonal Ab, which is raised against the S100
EF hand domain of HRNR, showed no immunoreactivity and
was not used for further analyses. In contrast, anti-HRNR2 and
anti-HRNR3 stained the stratum granulosum and SC, whereas
anti-HRNR4 exhibited a suprabasal staining of the epidermis
(Figure 4). In frozen sections (Figure 5; Figure S3), anti-HRNR2
and anti-HRNR4 both showed the same suprabasal-staining
pattern as HRNR4 in the paraffin-embedded tissues (Figure 4).
Notably, anti-HRNR3 exhibited no staining in the upper
epidermis in frozen sections (Figure S3) when compared with
paraffin-embedded sections (Figure 5). Preincubation of the
Abs with HRNR blocked immunoreactive HRNR in frozen skin
as well as in paraffin-embedded tissue. The infundibular outer
root sheath of normal human scalp hair follicles in anagen VI
showed the same strong suprabasal HRNR4-staining pattern as
the epidermis. In central and proximal parts, the entire outer
root sheath epithelium revealed homogeneous but slightly
weaker immunoreactivity with a decreasing intensity from
distal to proximal. HRNR3 showed a strong immunoreactivity
in the epidermis, which seemed to be even more intense in the
basal layer and the stratum spinosum. This strong immuno-
reactivity was present throughout the entire length of the outer
root sheath.
Lesional skin of atopic dermatitis (AD) and prominently of
psoriasis showed decreased HRNR immunoreactivity for anti-
HRNR2, anti-HRNR3, and anti-HRNR4 and is shown
exemplarily for anti-HRNR4 (Figure 6). Nonlesional skin of
both patient groups (n¼4) exhibited the same staining
pattern as healthy controls. Reduced expression of all HRNR
Abs in the SC of psoriatic lesions correlated with investiga-
tions in lesional psoriatic scale extracts, where we have not
been able to detect HRNR peptides by HPLC and mass
spectrometry, so far (data not shown).
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Figure 1. Amino acid sequence of hornerin. (a) Sequences of different domains (S100, EF-hand, repeat domains A1–A11, repeat domains B1–B10, and the C
terminus) are indicated. Locations of aromatic and long-chain aliphatic amino acids are shaded in different colors, Tyr (Y) red, Phe (F) blue, Trp (W) dark green,
Val (V) light green, Leu (L) yellow, and Ile (I) mint. Note the distribution of these amino acids within the repeat domains, which is characteristic for ‘‘glycine
loops’’ (Steinert et al., 1991). Peptides generated for domain-specific Abs are shown in sky blue. The stratum corneum-derived HRNR-peptide A11
(HRNR2591–2684) is shown in bold italics. Note the presence of Cys (C, white) in nearly all repeat domains B, but in none of the repeat domains A, except A3. (b)
The functional units of human HRNR are highly conserved. Multiple alignments of protein sequences of both A-type repeats (a) and B-type repeats (b) were
created with CLUSTALW. The corresponding repeat names are given on the left, whereas the total numbers of amino-acid residues of each repeat are given on
the right. The shading reflects more than 90% of identical or similar residues in each column. In each column, the more conserved residues were observed, the
darker color shaded. Conserved amino acids are indicated as white letters on a black background whereas similar amino acids are white letters on a gray
background.
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Figure 2. Hornerin mRNA is expressed at various localizations of human
skin. (a) HRNR mRNA expression obtained from tissue samples from different
skin localizations by RT–PCR. HRNR mRNA expression was quantified by
real-time PCR. Data were obtained from three skin specimens each and are
indicated as the mean±SD. (b) Comparative analysis of FLG/HRNR mRNA
expression. Data were obtained from three independent experiments and are
indicated as the mean±SD.
a
b
R
el
at
ive
 H
R
N
R
m
R
N
A 
ex
pr
es
sio
n
R
el
at
ive
 F
LG
m
R
N
A 
ex
pr
es
sio
n
0 d
Incubation time (days)
Incubation time (days)
2 d 4 d 6 d 8 d
0 d 2 d 4 d 6 d 8 d
20
10
0
450
400
350
300
250
200
150
100
50
0
Figure 3. Hornerin mRNA is expressed in cultured human keratinocytes.
Relative mRNA expression of either HRNR (a) or FLG (b) against GAPDH was
measured by real-time PCR in cultured primary keratinocytes of 80–100%
confluence in the presence of 1.7mM CaCl2 for up to 8 days. Data were
obtained from three independent cultures of three independent donors and
are indicated as the mean±SD.
Face
HRNR1
HRNR2
HRNR3
HRNR4
Legs Trunk Palmoplantar Blocked
Figure 4. Hornerin is expressed in healthy skin. Immunohistochemical analysis of hornerin expression in human skin at various localizations (in columns,
n¼ 4–8) using polyclonal goat Abs raised against four different peptides (HRNR1–4) of hornerin (in lines). Blocking of the antibody with the corresponding
recombinant antigen (0.125 mgml1) is shown in column ‘‘blocked’’. Bars indicate 50 mm. Representative results are shown.
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To further characterize the local expression of HRNR,
laser scanning microscopy was performed in paraffin-
embedded tissue (Figure 7). Anti-HRNR2 showed an epider-
mal expression pattern omitting the basal cell layer and
distinct foci of granular immunoreactivity within the stratum
granulosum and the SC. Anti-HRNR3 stained the stratum
granulosum more intensely, whereas anti-HRNR4 immuno-
reactivity was predominantly suprabasal. Our results indicate
that HRNR is constantly expressed in healthy human skin.
HRNR repeat-domain peptides exhibit unusual biochemical
properties
When full-length recombinant HRNR repeat-domain pep-
tides were analyzed, none of them could be stained by
commonly used protein stains, including Coomassie Blue,
silver (Figure S4), Ponceau-Red- and Ruthenium II tris
(bathophenanthroline disulfonate) (Pluder and Beck-Sickin-
ger, 2007), in contrast to the SUMO-His-tag fusion proteins
during recombinant generation of HRNR peptide fragments
(data not shown). Further, reversed-phase (RP)-HPLC analyses
of HRNR repeat-domain peptide preparations stored at
neutral pH, in particular HRNR3, revealed multiple peaks—
unlike HRNRs stored at pH 2, which elute in single peaks
(data not shown). To test the hypothesis that HRNR peptides
possibly undergo degradation at neutral pH, we performed
quadrupol-time-of-flight (QTOF) ESI–MS in 10mM ammo-
nium formate buffer, pH 6.5. These conditions allow soft
ionization of the peptides at non-denaturating conditions and
thus, owing to the presence of volatile buffers, analyses of
noncovalent peptide interactions in solution (Veenstra,
1999). Whereas storage of HRNR peptides in 0.01% acetic
Epidermis
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Figure 5. Hornerin is expressed in the hair follicle. Anti-HRNR4 Abs were
used to stain cryosections of the epidermis and a hair follicle. The distal parts
of the outer root sheet (ORS) show the same strong suprabasal staining
pattern, whereas in central and proximal parts the outer root sheet epithelium
reveals homogeneous, but much weaker immunoreactivity with a decreasing
intensity processing from distal to proximal. Inner root sheet (IRS), hair shaft
(HS), sweat glands (SG). Bars indicate 50 mm.
Atopic dermatitis
Psoriasis Psoriasis non-lesional
Atopic dermatitis non-lesional
Figure 6. Hornerin expression in atopic dermatitis and psoriasis patients.
Anti-HRNR4 immunoreactivity was analyzed in paraffin-embedded biopsies
of patients suffering from AD and psoriasis. The staining was compared with
nonlesional skin of the same patient at correlating sites (n¼4). Bars represent
50mm. Representative results of four different patients of each group are
shown.
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acid or aqueous trifluoroacetic acid (TFA) revealed a single
peak of the expected mass, HRNR peptides, stored in
ammonium formate buffer, pH 6.5, for 3 hours, resulted in
a nearly complete loss of the expected masses and a huge
number of additional peaks of both, higher and lower
molecular weight (MW) (Figure S5). In addition, a mixture
of HRNR2 and HRNR3 showed an ESI–MS spectrum, which
differed from the spectra of the single constituents (Figure S5).
Our findings imply that HRNR fragments are easily degraded
and have the capacity to form complex high MW aggregates.
HRNR repeat-domain peptides are fragile and form complex
mixtures in vitro and in vivo
Immunoblotting analyses were performed with four affinity-
purified HRNR Abs. HRNR1 Abs did not immunostain
epidermis and SC extracts (data not shown), and therefore
were not used for Western blot (WB) experiments. Owing to
the presence of several very similar AA sequence motifs in
HRNR repeat domains (HRNR2, HRNR3, and HRNR4;
Figure 1) used for immunization, these Abs expectedly show
some cross-reactivity. HRNR2 Abs cross-reacted weakly with
pH 2-stored HRNR3, but not with HRNR4 (Figure S6a);
HRNR3 Abs showed weak cross-reactivity with pH 2-stored
HRNR2, where they stain only a 45 kDa band (Figure S6b).
The same Abs strongly cross-reacted with HRNR2, when
stored at pH 6.5, and resulted in two to three bands (Figure
S6e). HRNR3 Abs did not cross-react with HRNR4 (Figure
S6b and e), whereas HRNR4 Abs cross-reacted with both
HRNR2 and HRNR3 (Figure S6c and f). To test whether these
Abs cross-react with ifapsoriasin/FLG-2, a protein that
shows a very close similarity to HRNR repeat domains, a
recombinant full-length FLG-2 repeat domain (FLG-2953–1029)
was generated. The absence of FLG-2 staining by an
HRNR–Abs mixture (Figure 8a, Figure S6h) as well as the
absence of any changes in the WB staining patterns when
FLG-2-blocked HRNR Abs were used (Figure 8f and Figure
S6i) shows that our Abs are specific for HRNR.
Although HRNR2, HRNR3, and HRNR4 were stained by
the respective Abs, no bands of the expected size (HRNR2:
9.4 kDa (Figure S6, a–i, lane 3); HRNR3: 6.6 kDa (Figure S6,
a–i, lane 2); HRNR4: 12.6 kDa (Figure S6, a–i, lane 1)) were
observed. Instead, single or multiple bands were seen in the
higher MW range (Figure 8 and Figure S6). HRNR peptides,
which were stored at pH 2, showed different WB staining
patterns than peptides stored at pH 6.5. The most marked
change was seen for HRNR3 after storage at pH 6.5 for
3 hours. These conditions led to a complete loss of antigenity
(Figures 6e and f, lane 2), possibly caused by degradation.
Mixtures of the HRNR-peptides showed WB staining patterns
that differed from those seen for pure peptides (Figure 8a, f
and Figure S6, a–c). For example, when HRNR3 Abs blocked
with HRNR2 and HRNR4 were used for WB with a mixture of
HRNR2, HRNR3, and HRNR4, a diffuse staining with
additional higher MW bands was observed, instead of a
single 16 kDa band of HRNR3 (Figure 8e). This implies that
HRNR peptides are fragile, easily degraded peptides that form
complex mixtures of peptides and high MW aggregates.
SDS/dithiothreitol (DTT) buffers, 8 M urea/DTT buffers as
well as SDS-buffers extracted dimmunoreactive HRNR from
epidermis and full thickness skin with strong and diffuse WB
bands at 250, 150, and 100 kDa (Figure 8a). SC extracts gave
strong WB staining with HRNR Abs, resulting in a laddering
effect between 50 and 150 kDa (Figure 8b–d). The use of
DTT-containing buffers for extraction of SC led to a band shift
(Figure 8a), which suggests additional Cys-bridge-bound
HRNR peptides. We observed similar, but not completely
identical staining patterns for the three HRNR Abs (Figure
8b–d) used. No difference was observed in the staining
pattern of SC extracts and epidermis extracts when HRNR
Abs were preabsorbed with FLG-2953–1029, a potential cross-
reacting epidermal protein (Figure 8f).
DISCUSSION
A previous study suggested that human HRNR is not present
in normal stratified epithelium, hair follicles, and most of
other human tissues (Takaishi et al., 2005). In that study
neither HRNR mRNA nor immunoreactivity with Abs
directed against a single 11 AA peptide, which represented
a boundary of repeat domains A and B, were found in healthy
skin (Takaishi et al., 2005). In our present investigation, we
identified a 9.2 kDa HRNR repeat-domain peptide in healthy
SC extracts indicating that healthy skin expresses HRNR. This
finding was further confirmed by qualitative and quantitative
RT-PCR analyses as well as immunohistochemistry of healthy
skin specimens from different body localizations.
Technical reasons discussed below may have caused the
discrepancy between the previous and our study. In mice,
both HRNR and FLG mRNA are abundant in normal skin and
a
HRNR2 HRNR3 HRNR4
b c
Figure 7. Immunofluorescence of hornerin in human skin. Immunofluorescent staining of paraffin-embedded tissue sections using polyclonal goat Abs directed
against HRNR2 (a), HRNR3 (b), and HRNR4 (c) shown in red. Bars represent 50mm. Note the differences of staining patterns of the three antibodies.
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the amount of HRNR mRNA was more than fourfold higher
than that of FLG mRNA (Makino et al., 2003). In contrast, in
most human skin specimens from different body sites, the
HRNR gene exhibits only weak transcription, approximately
10,000-fold lower than that of the FLG gene (Figure 5b),
making general RT–PCR analysis difficult. HRNR mRNA
expression was transiently upregulated during calcium-
induced keratinocyte differentiation. This was in contrast to
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Figure 8. Western blot (WB) analysis of HRNR expression in SC and epidermis extracts. Proteins were separated in a 9.5% tricine/urea gel and blotted from the
anode using protein transfer at pH 10.5. Recombinant HRNRs used here have been HPLC-purified, stored below 70 1C and used immediately before
experiments unless otherwise stated. (a) WB analysis of tissue extracts with a mixture of Abs toward HRNR2, HRNR3, and HRNR4. Lane 1: mixture of HRNR2,
HRNR3, and HRNR4, each 100 ng; lane 2: SDS/PBS epidermis extract, 24mg protein; lane 3: SDS/PBS/DTT epidermis extract, 30mg protein; lane 4: TRIS/
glycerol/SDS (TGS)/DTT full skin extract, 3.3mg protein; lane 5: SDS/PBS/8M ureaþDTT epidermis extract, 8.5 mg protein; lane 6: TGS/DTT SC extract, 12 mg
protein; lane 7: TGS SC extract, 12 mg protein; lane 8: filaggrin-two953–1029, 200 ng. Note the absence of any filaggrin-two953–1029 staining. (b) WB analysis with
an HRNR2 antibody. Lane 1: HRNR2, 100 ng; lane 2: TGSþDTT SC extract, 12 mg protein; lane 3: TGS SC extract, 12mg protein; lane 4: PBS SC extract, 12 mg
protein; lane 5: HRNR2, 200 ng. (c) WB analysis with an HRNR3 antibody. Lane 1: HRNR3, 100 ng; lane 2: TGSþDTT SC extract, 12 mg protein; lane 3: TGS SC
extract, 12mg protein; lane 4: PBS SC extract, 12 mg protein; lane 5: HRNR3, 100 ng. Arrows indicate the ladder-like staining pattern we often detected with
HRNR3 Abs. (d) WB analysis with an HRNR4 antibody. Lane 1: a mixture of HRNR2, HRNR3, and HRNR4, 100 ng each; lane 2: TGSþDTT SC extract, 12 mg
protein; lane 3: TGS SC extract, 14mg protein; lane 4: PBS SC extract, 12 mg protein; lane 5: HRNR4, 100 ng. Note the change of the staining pattern, when
HRNR4 is mixed with HRNR2 and HRNR3. (e) WB analysis with an HRNR3 antibody, blocked with HRNR2 and HRNR4. HRNR3 Abs were preincubated for
1 hour with HRNR2 and HRNR4 (10 mg each) and then used for WB: Lane 1: mixture of HRNR2 and HRNR4, each 100 ng; lane 2: mixture of HRNR2, HRNR3,
and HRNR4, each 100 ng; lanes 3 and 4: skin extracts (3.3 and 4.1 mg protein per lane). ‘‘#1’’ and ‘‘#2’’ indicate different skin-extracts. Lane 5: HRNR3, 100 ng.
Note the change of the staining pattern, when HRNR3 Abs are blocked with HRNR2 and HRNR4. When the same sample set was analyzed with HRNR3-
blocked (10 mg) anti-HRNR3, staining was absent (data not shown). (f) Cross-reactivity testing with FLG-2-blocked anti HRNR Abs. WB analysis shown in a was
repeated with the identical HRNR–antibody mixture, which was blocked with 5 mg FLG-2953–1029. Note the same WB staining pattern as shown in a.
Representative results out of 2–6 independent analyses are shown.
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FLG mRNA expression, which increased during the whole
period of the experiment. The weak expression of HRNR is
similar to that of RPTN (Huber et al., 2005), implying that
there are different induction pathways among the S100-fused
genes and therefore most likely different biological functions.
Using affinity-purified polyclonal Abs, directed against
four different recombinant 7–12 kDa HRNR-domain antigens,
we detected immunoreactive HRNR in all skin specimens
investigated. These Abs lacked cross-reactivity with a
recombinant repeat domain of the most closely related SFTP
FLG-2, which has 65, 73, and 81% identity in 15–31 AA
overlaps with HRNR2, HRNR3, and HRNR4, respectively,
suggesting HRNR-specific staining of the Abs. Cross-reactiv-
ity with FLG is unlikely, as profilaggrin exhibits only 36–39%
identity with HRNR2, HRNR3, and HRNR4.
Murine HRNR was reported to be widely expressed in
granular skin layers—similar to our findings with human
HRNR (Figure 7a). Furthermore, murine HRNR colocalizes
with profilaggrin in keratohyalin granules (Makino et al.,
2003) but is more frequently present in the periphery of the
granules in contrast to profilaggrin, which was reported to be
distributed equally within the granules. In our study, human
HRNR expression persisted in the SC, which was confirmed
by WB analyses. In lesions of psoriasis and AD, the
immunoreactivity of HRNR was reduced in the SC which
could be owing to enhanced proteolytic activities in these
lesions (Wiedow et al., 1992; Ekholm and Egelrud, 1999).
N-terminal spacer domain peptides of profilaggrin were
described to be transported to the nucleus (Pearton et al.,
2002). The absence of nuclear staining with HRNR1 Abs
suggests different properties of these S100-type fused proteins
in this respect. As no staining of HRNR1 was observed at
other sites, it is tempting to speculate that the N-terminal part
of HRNR might be cleaved and digested rapidly after
translation.
To verify our IHC results by WB, we studied first
electrophoretic mobility of recombinant HRNR peptides.
These could not be stained by any of the protein-staining
techniques, a unique property reported also for glycine–
glutamine rich proteins such as glutenin repeats (Feeney
et al., 2001). The observed WB band patterns suggest a
preferential formation of HRNR dimers and multimers,
a behavior also observed for glycine/serine repeat-domain
containing fusion proteins of corneodesmosin (Caubet et al.,
2004). ESI–MS analyses clearly indicated the presence of
high MW complexes characteristic of HRNR cleavage
products when stored at pH 6.5. The HRNR degrad-
ation mechanism remains elusive. The unique property of
HRNR peptides to be spontaneously degraded at neutral pH
may generate AAs such as it is proposed for FLG. Similar as
FLG, HRNR contains glutamine, which is known to be the
source of the natural moisturizing factor pyrrolidone
carboxylic acid. HRNR could contribute to skin moisturizing
by forming natural moisturizing factor in a similar way as
proposed for FLG (Scott and Harding, 1986; Rawlings et al.,
1994).
The biological function of HRNR remains unknown.
Previous studies on mouse HRNR may suggest that
HRNR is involved similar to those of FLG in the
cornifying epithelium (Makino et al., 2001, 2003). FLG
functions as an intermediate filament-associated protein that
aggregates the keratin cytoskeleton system to form a dense
protein lipid matrix that is cross-linked by transglutaminases
to form the cornified cell envelope (Dale et al., 1978).
Null mutations in the exon 3 of the FLG gene cause ichthyosis
vulgaris (Smith et al., 2006) and two other highly
prevalent null mutations predispose European individuals to
early onset AD (Palmer et al., 2006), which firmly establishes
the importance of skin barrier dysfunction in the develop-
ment of AD and its associated diseases (Irvine, 2007).
Compared with FLG, HRNR repeat domains are not as rich
in glutamine, which may result in reduced cross-linkage by
transglutaminases. Ninety-five percent of the whole HRNR
consists in quasi-repetitive, glycine/serine-rich peptide se-
quences, which contain a number of aromatic (Tyr (Y),
Phe (F), Trp (W)), and a few long-chain aliphatic (Val (V), Leu
(L), Ile (I)) AAs (Figure 1). Domains with these structural
motifs, termed ‘‘glycine loops’’ (Steinert et al., 1991), are
found in keratins (Steinert et al., 1983), loricrin (Hohl et al.,
1991) as well as corneodesmosin (Jonca et al., 2002).
‘‘Glycine-loops’’ have been associated with protein elastic
behavior and protein motion as seen in Bombyx mori silk
sericin, a protein glue that ensures the cohesion of the
cocoon threads and spider silk proteins (Xu and Lewis,
1990; Smith et al., 1999; Altman et al., 2003). In a
similar way, high MW glutenin subunits are thought
to be largely responsible for the elastic properties of gluten,
which defines dough strength (Anjum et al., 2007). In
addition, there is experimental evidence that the N-terminal
glycine loop domain of corneodesmosin is essential for its
adhesive properties (Caubet et al., 2004). It is tempting
to speculate, therefore, that HRNR’s biological function
includes elastic and/or adhesive properties. These
elastic properties might also be important within the
hair follicle epithelium, which represents a long, tissue
column that extends deep into the subcutis and therefore is
constantly exposed to substantial shear and condensation
stress whenever hair follicle-bearing skin is stretched or
compressed.
In summary, we were able to identify HRNR as an
abundantly expressed protein in healthy human skin with
unusual biochemical characteristics including auto-degrad-
ing properties of oligomeric complexes. Further studies will
be necessary for a better understanding of HRNR’s role in
skin barrier function and in skin diseases.
MATERIALS AND METHODS
All experiments were performed according to the Declaration of
Helsinki Principles and with appropriate ethics committee approval
of the University Kiel. Skin samples were obtained from untreated
patients with AD and psoriasis vulgaris in local anesthesia after
having given written informed consent. In addition, skin samples
were obtained from nonaffected sites of patients undergoing surgical
excision of skin tumors (nevi, non-melanoma skin neoplasms).
Reagents were obtained from Sigma-Aldrich (Taufkirchen, Germany)
unless otherwise indicated.
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Isolation of polar peptides from human stratum corneum
Pooled heel SC (80–120 g) was extracted with acidic ethanolic citrate
buffer as described (Schro¨der, 1997). Isolation and purification of
polar peptides and proteins was performed as previously described
(Harder et al., 2001; Harder and Schro¨der, 2002; Gla¨ser et al.,
2005). HPLC fractions were analyzed by ESI–MS analyses as
described (Gla¨ser et al., 2005). Concentrations of proteins present
in HPLC fractions were estimated via UV absorbance integration at
215 nm using ubiquitin for calibration.
Protein sequencing
N-terminal AA sequence analysis was performed with a pulsed
liquid-phase 776 automated protein sequencer (Perkin-Elmer
Applied Biosystems, Rodgau, Germany).
Primary keratinocyte cultures
Primary keratinocytes were prepared from surgical samples of
juvenile foreskin tissue following established methods (Wiedow
et al., 1998) and were cultured in EpiLife-medium containing
0.05mM Ca2þ . For stimulation and RNA isolation, cells were grown
in six-well culture plates (9.6 cm2 per well; Falcon, Heidelberg,
Germany) and were used after the second passage at a confluence of
80–100%. To induce differentiation, cells were grown in the
presence of 1.7mM of Ca2þ for the indicated time and viability
was checked daily by microscope inspection.
RNA isolation and cDNA synthesis
Total RNA was isolated from human skin or cultured foreskin-
derived keratinocytes with the RNeasy Mini kit (Qiagen, Hilden,
Germany). A total of 2mg of total RNA was reverse transcribed with
an oligo(dT)18 primer and Superscript II RNaseH
 RT (Invitrogen,
Hamburg, Germany). The reaction mixture was diluted 10-fold with
H2O for RT–PCR experiments.
PCR analyses
Qualitative RT-PCR assay was performed with Advantage 2
Polymerase Mix (BD Bioscience Clontech, Heidelberg, Germany).
One pair of gene-specific PCR primers (P-A1-F: 50-CCTACAA
GGCGTCATCACTGTCATCG-30; P-A1-R: 50-TCAGTCCCAGGTTT
AAGACTTCCTCTGACG-30) were designed to overlap intron 2 of
the HRNR gene and amplify the 447-bp cDNA target. The thermal
cycling conditions were as follows: firstly with 5 cycles at 95 1C for
20 seconds, 72 1C for 45 seconds; then 35 cycles at 95 1C for
20 seconds, 70 1C for 45 seconds. The PCR products were separated
on a 2.0% agarose gel and then visualized by ethidium bromide
staining. The specificity of the PCR products was confirmed by
sequencing when necessary.
Quantitative real-time RT-PCR assays were carried out using a
SYBR Premix Ex Taq Kit (Takara Bio, Heidelberg, Germany) in a
fluorescence thermocycler following the instructions of the manu-
facturer (LightCycler; Roche Molecular Biochemicals, Hamburg,
Germany). Cycling conditions were as follows: 45 cycles at 95 1C for
10 seconds, then 72 1C for 20 seconds (‘‘touchdown’’ of 1 1C per
cycle to 66 1C). The PCR products were separated on a 2.0% agarose
gel and then visualized by ethidium bromide staining. The specificity
of the PCR products was confirmed by the MW of the products and a
melting curves analysis at each data point. As an internal control to
account for keratinocyte differentiation in response to Ca2þ
stimulation, the FLG gene was measured with each cDNA in a
separate PCR reaction using intron-spanning primers (forward
primer: 50-GGCTCCTTCAGGCTACATTCTA-30, reverse primer: 50-
ATCTGGATTCTTCAGGATTTGC-30). Cycling conditions were as
follows: 45 cycles at 95 1C for 10 seconds, 69 1C for 20 seconds
(‘‘touchdown’’ of 1 1C per cycle to 63 1C), 72 1C for 15 seconds,
then 76 1C acquisition of signals. To calculate the relative transcripts
amplification, the housekeeping gene glyceraldehyde phosphodehy-
drogenase (GAPDH) was assessed with each cDNA in a separate
PCR reaction by one pair of intron-spanning primers (forward primer:
50-CCAGCCGAGCCACATCGCTC-30, reverse primer: 50-ATGAGCC
CCAGCCTTCTCCAT-30). Conditions for real-time PCR were opti-
mized in a thermal cycler (Robocycler gradient 96, Stratagene). The
purified cDNA corresponding to the related sequence of GAPDH,
FLG, or HRNR mRNA was used to calibrate standard curves,
respectively. Data from triplicate samples were analyzed and
expressed as mean±SD of mRNA in relation to the expression of
GAPDH.
Recombinant expression of HRNR peptide fragments
Four recombinant HRNR peptides (HRNR1, residues 49–98; HRNR2,
residues 1,075–1,172; HRNR3, residues 2,591–2,662; and HRNR4,
residues 2,727–2,850) were expressed. First we attempted to
generate HRNR repeat-domain peptides using a thioredoxin-
reductase-(His)6-HRNR fusion protein, which had to be cleaved by
enterokinase to liberate the full-length HRNR peptide. To subclone
into the expression vector pET-32a (Novagen, North Ryde,
Australia), PCR was performed with Pfu DNA polymerase (Promega,
Mannhein, Germany) under the following conditions: 45 seconds at
98 1C; 5 cycles (45 seconds at 98 1C; 45 seconds at 55 1C; 1minutes
at 72 1C); 25 cycles (45 seconds at 98 1C; 1minutes at 72 1C). The
inserts were cut with Bgl II and Not I, gel purified and inserted into
the pET-32a vector that had been double-digested with Bgl II and
Not I. Although the fusion protein could be generated, all of our
attempts to generate full-length HRNR peptides failed. In particular,
the HRNR3 fusion protein was found to be extremely sensitive
toward treatment with enterokinase resulting in excessive degrada-
tion. Using a different strategy, we could generate defined HRNR
peptides from SUMO-His-tag fusion proteins. To subclone into the
expression vector pET-SUMO (Invitrogen), PCR was performed with
Pfu DNA polymerase for 30 cycles (45 seconds at 98 1C; 45 seconds
at 55 1C; 1minutes at 72 1C). The inserts were gel purified and
inserted into the pET-SUMO vector. Specific primer pairs used in this
study are listed in Table S2. All positive clones were identified and
verified by sequencing. The plasmids were introduced into the
E. coli host strain BL21(DE3)pLysS (Novagen). Subsequently, these
were grown at 37 1C in tryptic soy broth medium containing
appropriate antibiotics. Expression of the recombinant protein was
induced with 1mM isopropyl thio-b-D-galactoside for 3 hours at
37 1C. Bacteria were harvested by centrifugation at 5,000 g for
5minutes at 4 1C, lyzed by sonication, and then centrifugated at
18,000 g for 30minutes at 4 1C (Beckman Coulter, Krefeld,
Germany). Recombinant proteins were trapped with Ni2þ -prepared
columns (Macherey-Nagel, Dueren, Germany) and Ni2þ -affinity
column-bound proteins were subjected to preparative RP-HPLC with
a column (SP250/10 Nucleosil 300-7 C8; Macherey-Nagel) that was
previously equilibrated with 0.1% (v/v) TFA in HPLC-grade water
containing 10% acetonitrile. The polyhistidine-tagged fusion
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proteins were eluted with a gradient of increasing concentrations of
acetonitrile containing 0.1% (v/v) TFA (flow rate, 3mlmin1).
Fractions containing UV (215 nm)-absorbing material were col-
lected, lyophilized, and analyzed by ESI–QTOF–mass spectrometry
(Micromass, Manchester, UK). Purified histidine-tagged SUMO
fusion proteins were then digested with SUMO protease 1 (Life-
sensors Inc., PA) according to the manufacturer’s suggestion. The
target peptide was purified by RP-HPLC with a Jupiter-5m-C4-300A
HPLC column (Phenomenex, Aschaffenburg, Germany) equilibrated
with 0.1% TFA in 10% acetonitrile. Peptides were eluted with a
gradient of increasing concentrations of acetonitrile containing 0.1%
(v/v) TFA (flow rate, 0.5mlmin1). Fractions of each peak were
collected. Purity of recombinant fusion proteins was determined by
SDS-PAGE. Briefly, proteins were separated on NuPAGE Novex 10%
Bis–Tris gels with MES SDS buffer (Invitrogen). Fusion proteins in
Bis–Tris gels were stained either with silver nitrate (Sigma, St Louis)
or Coomassie blue R-250 (Sigma). The SeeBlue Plus 2 Pre-stained
Standard marker (Invitrogen) was used as MW markers. The
polypeptide purity and molecular masses were assessed using
QTOF–ESI–MS. Masses of fusion proteins and recombinant HRNR
peptides are listed in Table S3. Concentrations of proteins present in
HPLC fractions were estimated by ultraviolet absorbance integration
at 215 nm using ubiquitin (Sigma) for calibration. Because HRNR
shows some homology to the related FLG-2, a domain of FLG-2
(FLG-2953–1029) was expressed using the SUMO system as described
above. Primers were: 50-tcaggctcaggtcaatcct-30 and 50-tcacctgtgttgtc-
caaagc-30. The expression product was digested with SUMO
Protease 1 and purified as described above, further analyzed by
ESI–MS as described below, and resulted in a peptide with 7525.2Da
(expected 7525.4Da).
ESI–MS analyses
Protein and peptide mass determinations were performed by ESI–MS
analyses using a Quadrupol-Time-of-Flight-Hybrid-Mass-spectro-
meter (Q-TOF II; Waters Micromass, Milford, MA) equipped with
an orthogonal electrospray source (Z-spray) operated in positive
ionization mode. For MS analysis aliquots (2–10 ml) of HPLC fractions
containing the sample were diluted with 100 ml carrier solvent
(50:50 acetonitrile:water containing 0.2% formic acid or 60:40
methanol: 10mM ammonium formate, pH 6.5) and infused into the
electrospray source at a rate of 10–20 mlmin1. Sodium iodide was
used for mass calibration for a calibration range of charge-to-mass
100–2,000. The capillary potential was set to 3.5 or 4 kV and cone
voltages between 25 and 75V were chosen; cone temperature was
set to 80 1C; desolvation temperature was 150 1C; the ESI gas was
nitrogen. The charge-to-mass ratio of ions was scanned in the range
of 280–2,000.
Acquisition and data analysis were all performed using the
MassLynx 4 software package supplied by Waters Micromass. Mass
spectra were averaged typically over 2–10 scans (2–20 s per scan).
The multiply charged raw data of intact proteins were background-
subtracted and deconvoluted using maximum entropy 1 to obtain
singly charged ion mass spectra to determine average molecular
masses of intact proteins. The raw combined spectral data from small
peptides or obtained after MS–MS fragmentation of selected
precursor ions were background subtracted and subjected to
maximum entropy 3 deconvolution to determine monoisotopic
molecular masses. Sample identity was determined by database
search analysis of peptide fragment mass patterns and/or after de
novo sequencing of tryptic peptide fragments. All mass fingerprint
and MS–MS data were searched against the human protein database
using the Mascot program (Matrix Science, Boston, MA). Peptide
sequences were directly (‘‘de novo’’) determined from MS–MS data
using the software program PepSeq from the MassLynx4 software
package (Waters Micromass). PepSeq-derived peptide sequences
were analyzed with the NCBI-BLAST protein database search
program.
Generation of goat antisera
Goat polyclonal antisera were generated against recombinant HRNR
peptides except for HRNR1, where the pET-32a-derived fusion protein
served as the immunogen (for sequences see Table S1): Abs-1 against
HRNR1 (residues 49–98), Abs-2 against HRNR2 (residues
1,075–1,172), Abs-3 against HRNR3 (residues 2,591–2,662) and
Abs-4 against HRNR4 (residues 2,727–2,850). A total of 1.0mg of a
protein mixture including 500 mg of the pET-32a-derived fusion
protein and 500mg of the RP-HPLC-purified recombinant HRNR-
peptide (or combined enterokinase-digests) was conjugated by the
glutaraldehyde method (Briand et al., 1985) to maleimide-activated
keyhole limpet hemocyanin (protein keyhole limpet hemocyanin
1:1, w/w) and used as immunogens. Immunization of a goat was
carried out four times on days 0, 14, 28, and 35. Goats were bled 2
weeks after the last booster. Abs were affinity purified. Briefly,
antisera were first applied to a thioredoxin-(His)6-affinity column to
deplete HRNR antisera from traces of His-tag Abs. Then affinity-
purified HRNR-Abs were obtained by absorption against RP-HPLC-
purified recombinant HRNR2, HRNR3, or HRNR4 peptides or the
pET-32a-HRNR1 fusion proteins that have been covalently bound to
HiTrap NHS-activated HP 1ml columns (Amersham Biosciences,
Freiburg, Germany). Specificity was tested by immuno-dot analyses
and western blot using purified HRNR peptides and thioredoxin-
(His)6. All Abs were free of FLG-2 and thioredoxin-(His)6 cross-
reactivity.
Extraction of skin samples
Abdominal skin or pooled healthy person’s heel SC was ground in
liquid nitrogen in the presence of washed hydrochloric acid-treated
sea sand. The fine-grained powder was vortexed thoroughly with
500ml phosphate-buffered saline (PBS) containing complete protease
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) per
100mg skin or SC and centrifuged. Unless otherwise indicated, all
centrifugation steps were carried out at 11,900 g for 10minutes.
After separation of supernatants, 500ml Tris/glycerol/SDS
(TGS)-buffer (5% SDS, 10% glycerol, 62.5mM Tris-HCl, complete
protease inhibitor cocktail) was added, resuspended, and centri-
fuged. The supernatants were removed, 500ml TGS/DTT (TGS plus
10mM DTT and complete protease inhibitor cocktail) were added to
the sediment, vortexed, incubated for 1.5 hours at room temperature,
centrifuged again and finally, the supernatants were collected.
Epidermis was isolated from fat-depleted abdominal
skin pieces, by incubation at 37 1C for 1 hour in PBS and in 10mM
EDTA containing complete protease inhibitor cocktail, and snap-
frozen in liquid nitrogen. Each 100mg epidermis was homogenized
in 500ml urea buffer (8M urea, 10mM EDTA, 50mM Tris-HCl pH
8.0, 10mM DTT with complete protease inhibitor cocktail; adapted
from reference (Resing et al., 1984)) or in an alternative approach
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extracted with PBS, TGS buffer, and TGS plus DTT using a Potter S
Homogenizer (B Braun Biotech International, Melsungen, Germany)
at 600 r.p.m. The urea extraction was centrifuged at 20,000 g for
30minutes and supernatants were further treated as described for full
skin extracts and SC samples. The protein concentration of the
extracts was determined using the Bicinchoninic Acid Protein
Assay Kit (Sigma) according to the manufacturer’s protocol.
Concentrations were determined in reference to a bovine serum
albumin standard.
Immunoblotting analyses
SC extract or skin extracts or 100–200 ng recombinant HRNR
peptides were loaded per lane onto a 9.5% SDS-tricine PAGE
containing 6M urea. As MW markers served chemiluminescent
prestained protein MW markers (Precision Plus Protein WesternC
Standards; Bio-Rad, Hercules, CA). Proteins were transferred to
protran–nitrocellulose membranes (Schleicher & Schuell,
BioScience, Dassel, Germany), located at both anode and cathode
at pH 10.5 (10mM NaHCO3, 3mM Na2CO3, 20% ethanol), blocked
for 1 hour in blocking buffer (5% (w/v) nonfat powdered milk in
PBSþ 0.05% Tween), and then incubated for 18 hours at 4 1C in 3%
(w/v) nonfat powdered milk in PBSþ 0.05% Tween containing
1:2,000 affinity-purified polyclonal HRNR Abs (HRNR1, HRNR2,
HRNR3, or HRNR4, respectively) or mouse anti-FLG-5 Ab (R&D
systems, Wiesbaden, Germany). The membrane was washed with
PBSþ 0.05% Tween six times for 5minutes each, then incubated for
1 hour in 3% (w/v) nonfat powdered milk in PBSþ 0.05% Tween
containing 1:20,000 dilution of mouse anti-goat IgG HRP conjugate
(Dianova, Hamburg, Germany). After six times washing, the
membrane was incubated for 5minutes with chemiluminescent
peroxidase substrate and visualized using a Diana III cooled CCD
camera imaging system.
Immunohistochemistry
Fixation of the tissue samples was performed in 4% paraformalde-
hyde. Paraffin sections (5 mm) of the tissue samples were depar-
affinized and rehydrated before heat-induced antigen retrieval was
performed in 0.01 M citrate buffer (pH 6.0). They were subsequently
blocked with normal 0.1% BSA and incubated for 60minutes with
appropriately diluted (1:150 to 1:2,000) affinity-purified polyclonal
goat HRNR Abs (anti-HRNR1, anti-HRNR2, anti-HRNR3, anti-
HRNR4). The sections were incubated with a biotinylated anti-goat
IgG (Vector, Burlingame, CA), followed by incubation with the
Vectastain ABC-AP system (Vector), developed with Vector Red or
Fast Red (Sigma) and counterstained with hematoxylin. Specificity
testing was performed by blocking the primary Ab with the
correlating recombinant HRNR peptide and negative control
straining was performed by omitting the primary Ab. Cross-reactivity
against different HRNR domains was tested for HRNR2, HRNR3, and
HRNR4 as well as against FLG-2953–1029 in paraffin-embedded tissue
(Figure S2a). To analyze the distribution of HRNR in hair follicles,
normal human scalp skin (obtained from five female patients
undergoing routine face-lift surgery after informed consent) was
embedded in Shandon Cryomatrix (Anatomical Pathology Inter-
national, London, UK) and frozen in liquid nitrogen. Samples were
cut in 7-mm-thick cryosections and stored at 80 1C until stained.
Sections were air-dried and fixed in acetone (20 1C). Immuno-
reactivity was detected as stated above.
Immunofluorescence
Paraffin-embedded human skin was used for indirect immunofluor-
escence staining of HRNR. Unspecific Ab binding was blocked with
0.1% BSA and 0.2% glycine in Tris-buffered saline. HRNR1–HRNR4
Abs were applied in a 1:200 dilution. As secondary reagent, Cy2-
coupled pig anti-goat-IgG (Dianova) was applied according to the
manufacturer’s recommendations. Nuclei were counterstained with
bisbenzimide (Hoechst 33258) and sections were analyzed by
confocal laser scanning microscopy (Zeiss, LSM 510 UV, Jena,
Germany). Slides of the same paraffin-embedded tissue were
analyzed without Ab-incubation in the same way to evaluate auto-
fluorescence, which was not detectable (data not shown). Secondary
Abs were controlled by omitting the first Ab and resulted in the
absence of fluorescent staining.
Bioinformatics
The multiple alignment of protein sequences was performed with
CLUSTALW (Notredame et al., 2000) and shading of the aligned
sequences was performed using BOXSHADE (http://www.ch.
embnet.org/software/BOX_form.html).
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